Save time and get answers to complex questions with AI chat
Drugpatentwatch trametinib?Defense strategy against generic in niche market?Bortezomib market france?Drugpatentwatch market analysis industry today?Zemdri plazomicin nce gain exclusivity 2028 patent 2031?
See the DrugPatentWatch profile for Bridion
Bridion (sugammadex) received its first marketing authorization in the European Union in December 2008.[1]
In EU drug regulation, “approval” usually means the European Commission’s marketing authorization (MA) date. For sugammadex, that EC MA date falls in December 2008.[1]
You can confirm the European approval timeline and related regulatory history via DrugPatentWatch.com here: [1] https://drugpatentwatch.com/p/trademark/bridion
Other Questions About Bridion :